Waldenström Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenström Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-12-22Clinical Trial Update: A Phase II Study of Doxycycline in Relapsed NHL [Phase 2]
Phase II trial of doxycycline in relapsed non-Hodgkin lymphoma was terminated and results were posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-11-23Clinical Trial Update: PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]
Clinical trial update comparing PCD versus RCD regimens for Waldenström's macroglobulinemia in Phase 1/2; current status is not specified.
-
CLINICAL_TRIALS trial_result · 2016-07-25Clinical Trial Update: Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia [Phase 1]
A Phase 1 trial of pomalidomide, dexamethasone, and rituximab in Waldenström's macroglobulinemia was terminated, with results posted in 2016…
-
CLINICAL_TRIALS withdrawal · 2016-07-14Clinical Trial Update: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies [Phase 2]
A Phase 2 clinical trial evaluating single or double donor umbilical cord blood transplant for high-risk hematologic malignancies has been w…
-
CLINICAL_TRIALS trial_result · 2016-06-10Clinical Trial Update: Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia [Phase 2]
Phase 2 study evaluating ofatumumab with bortezomib in previously untreated Waldenström macroglobulinemia was terminated; results were poste…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-03-21FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) filed by Pharmacyclics LLC. The document indicates FDA action on a supplem…
-
CLINICAL_TRIALS trial_result · 2015-12-17Clinical Trial Update: Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a radiolabeled monoclonal antibody with rituximab, with/without filgrastim and interleukin-11, in relapsed or r…
-
CLINICAL_TRIALS trial_result · 2015-12-16Clinical Trial Update: Simvastatin in Waldenstrom's Macroglobulinemia [Phase 2]
A Phase 2 clinical trial of simvastatin for Waldenström's macroglobulinemia was terminated, with results posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-12-16Clinical Trial Update: CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 trial of lenalidomide plus rituximab in Waldenström's macroglobulinemia was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2015-12-03Clinical Trial Update: Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies [Phase 1]
Phase 1 safety study of carfilzomib (PR-171) in hematologic malignancies has completed and results were posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-11-26Clinical Trial Update: Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of lenalidomide plus rituximab as maintenance therapy for adult B-cell non-Hodgkin lymphoma is noted as terminated.
-
CLINICAL_TRIALS trial_result · 2015-08-19Clinical Trial Update: Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia [Phase 3]
A Phase 3 trial compares chlorambucil with fludarabine in patients with advanced Waldenström macroglobulinemia. The study also covers lympho…
-
CLINICAL_TRIALS trial_result · 2015-04-15Clinical Trial Update: Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease [Phase 2]
Phase 2 trial update reporting completion of a study evaluating interleukin-12 in patients with various previously treated non-Hodgkin lymph…
-
CLINICAL_TRIALS trial_result · 2015-04-03Clinical Trial Update: S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
A SWOG trial (NCT00919139) evaluating a blood/bone marrow repository from patients with multiple myeloma, smoldering myeloma, Waldenström's …
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 trial evaluating high-dose melphalan with peripheral stem cell transplantation followed by interferon alfa in Waldenström's macroglo…
-
CLINICAL_TRIALS withdrawal · 2015-03-06Clinical Trial Update: S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia [Phase 2]
A Phase 2 SWOG trial evaluating observation or combination chemotherapy with bortezomib, thalidomide, and rituximab followed by two autologo…
-
CLINICAL_TRIALS trial_result · 2015-02-18Clinical Trial Update: Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia [Phase 2]
A Phase 2 trial of bortezomib, dexamethasone, and rituximab in untreated Waldenström macroglobulinemia has been completed. The update notes …
-
CLINICAL_TRIALS trial_result · 2015-02-18Clinical Trial Update: Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial evaluating Rituximab with chemotherapy and 90-yttrium ibritumomab tiuxetan in patients with Stage I or II non-Hodgkin lympho…
-
CLINICAL_TRIALS trial_result · 2015-01-27Clinical Trial Update: Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating rituximab, cyclophosphamide, bortezomib, and dexamethasone in relapsed/refractory low-grade follicular lym…
-
CLINICAL_TRIALS trial_result · 2014-12-23Clinical Trial Update: Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms [Phase 1]
A Phase 1 trial evaluating the combination of bortezomib and flavopiridol in patients with recurrent or refractory indolent B-cell neoplasms…
-
CLINICAL_TRIALS trial_result · 2014-10-06Clinical Trial Update: Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This ClinicalTrials.gov update reports a terminated phase 1/2 trial evaluating fenretinide with rituximab for B-cell non-Hodgkin lymphomas; …
-
CLINICAL_TRIALS trial_result · 2014-09-01Clinical Trial Update: Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating agatolimod sodium in combination with rituximab and Yttrium-90 ibritumomab tiuxetan for adults with re…
-
CLINICAL_TRIALS trial_result · 2014-08-06Clinical Trial Update: Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial update evaluating the combination of iodine-131 tositumomab with fludarabine phosphate in older patients undergoing autologous…
-
CLINICAL_TRIALS trial_result · 2014-06-16Clinical Trial Update: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 clinical trial of everolimus (RAD001) as primary therapy for Waldenstrom's Macroglobulinemia completed with results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-06-02Clinical Trial Update: Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 trial evaluating thalidomide plus rituximab in Waldenström's macroglobulinemia has completed, with results posted in 2014.